Development of resistance by cancer cells has proven to be one of the most frequent causes of targeted therapy failure and may account for the low efficacy of therapies targeting the Shh pathway in MB.38, 39 mTORC1 pharmacological inhibition can overcome the acquired resistance to Shh targeted therapy in Shh group MBs.40 Our study shows that inhibition of LAT1 leads to a strong decrease in mTORC1 activity, suggesting that the use of JPH203 may be relevant to bypass resistance to Shh targeted therapies. This evidence concerns the gene SLC7A5 and Mobius syndrome.